Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected adults aged more than or equal to 18 years~2. Received ritonavir boosted PI-based HAART for \>3 months prior screening visit~3. History of HIV RNA \< 50 copies/ml within 12 months prior to screening visit~4. HIV-RNA \< 50 copies/ml at screening visit~5. Signed written informed consent~Exclusion Criteria:~1. Active AIDS-defining disease or active opportunistic infection~2. History of virological failure (plasma HIV-RNA ≥1,000 copies/ml) while using any ritonavir boosted PI-based HAART~3. Pregnancy or lactation at screening visit~4. Relevant history or current conditions or illnesses that might interfere with drug absorption, distribution, metabolism or excretion e.g. chronic diarrhea, malabsorption~5. Use of concomitant medication that may interfere with the pharmacokinetics of the study drugs e.g. rifampicin, proton pump inhibitor~6. History of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study~7. ALT ≥200 IU/L at screening visit~8. Creatinine clearance \< 60 c.c. per min by Cockroft-Gault formula at screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ATV/r 200 mg/100 mg OD
- 2 (Type: EXPERIMENTAL): ATV/r 300 mg/100 mg OD

Based on this trial design, predict the completion outcome and termination type (if applicable).